Keywords: pSivida, Pfizer, Latanoprost, Glaucoma, Ocular hypertension, Durasert

pSivida to receive up to $168 million plus royalties under revised deal with Pfizer; starts new clinical study

Article | 15 June 2011

Print This

USA-based drug delivery firm pSivida (Nasdaq: PSDV; ASX:PVA) says it has amended its 2007 $165 million R&D deal with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in